The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis
Abstract
IMPORTANCE: Data on outcomes following surgical management of intrahepatic cholangiocarcinoma (ICC) are limited. The incidence of ICC is increasing and it has a poor prognosis. No consensus has been reached regarding the optimal treatment modalities. OBJECTIVE: To systematically review and synthesize the available evidence regarding treatment and prognosis in patients with ICC. DATA SOURCES: The PubMed database was searched for relevant articles published between January 1, 2000, and April 1, 2013. STUDY SELECTION: Only studies assessing predictors of survival or recurrence in patients undergoing curative-intent surgical treatment of ICC were included. Small series, studies reporting on mixed types of cholangiocarcinoma, or exclusively on hepatolithiasis-associated cholangiocarcinoma, and those published in a language other than English, French, German, Italian, or Greek, were excluded. Fifty-seven of 960 articles were therefore analyzed. DATA EXTRACTION AND SYNTHESIS: Data on preoperative, intraoperative, and postoperative variables were extracted by 3 independent reviewers. Multiple studies reporting on the same population were excluded. Data were pooled using a random-effects model. MAIN OUTCOMES AND MEASURES: We hypothesized that preoperative variables and tumor characteristics affect patient survival. The outcomes of the study were overall survival and recurrence-free survival. The hypothesis was formulated before data collection. RESULTS: Fifty-seven studies (4756 patients) were included in the review. Median patient age ranged from 49 to 67 years, and 57% were male. Most patients had a solitary (69%), large (median size, 4.5-8.0 cm) tumor of the mass-forming type (86%). Approximately one-third of the patients had lymph node metastasis (34%) or vascular (38%), perineural (29%), or biliary invasion (29%). Most underwent a major hepatectomy (82%), often accompanied by lymphadenectomy (67%) and sometimes by extrahepatic bile duct resection (23%). Median and 5-year overall survival (OS) generally were approximately 28 months (range, 9-53 months) and 30% (range, 5%-56%), respectively; factors predicting shorter OS included large tumor size, multiple tumors, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy or radiotherapy did not appear to be beneficial. Seven studies (2132 patients) provided data for the meta-analysis. Factors associated with shorter OS included older age (pooled hazard ratio, 1.10; 95% CI, 1.03-1.17), larger tumor size (1.09; 1.02-1.16), presence of multiple tumors (1.70; 1.43-2.02), lymph node metastasis (2.09; 1.80-2.43), vascular invasion (1.87; 1.44-2.42), and poor tumor differentiation (1.41; 1.17-1.71). CONCLUSIONS AND RELEVANCE: The prognosis of ICC is dictated mainly by tumor factors. Future research could focus on the usefulness of adjuvant treatment as well as other multidisciplinary treatment modalities.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
(2017) · Springer eBooks · doi:10.1007/978-3-319-40618-3 · Cited by 17,242
Parmar, M. K. B., Torri, V., & Stewart, L. (1998) · Statistics in Medicine · doi:10.1002/(sici)1097-0258(19981230)17:24<2815::aid-sim110>3.0.co;2-8 · Cited by 4,802
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer
Valle, J., Wasan, H., Palmer, D. H., Cunningham, D., Anthoney, A., Maraveyas, A., Madhusudan, S., Iveson, T., Hughes, S., Pereira, S. P., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908721 · Cited by 4,406
Cholangiocarcinoma: Thirty-one-Year Experience With 564 Patients at a Single Institution
DeOliveira, M. L., Cunningham, S. C., Cameron, J. L., Kamangar, F., Winter, J. M., Lillemoe, K. D., Choti, M. A., Yeo, C. J., & Schulick, R. D. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000251366.62632.d3 · Cited by 1,300
The Epidemiology of Cholangiocarcinoma
Shaib, Y., & El-Serag, H. (2004) · Seminars in Liver Disease · doi:10.1055/s-2004-828889 · Cited by 1,132
Prognostic Nomogram for Intrahepatic Cholangiocarcinoma After Partial Hepatectomy
Wang, Y., Li, J., Xia, Y., Gong, R., Wang, K., Yan, Z., Wan, X., Liu, G., Wu, D., Shi, L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.5984 · Cited by 1,057
Increasing Incidence and Mortality of Primary Intrahepatic Cholangiocarcinoma in the United States
Patel, T. (2001) · Hepatology · doi:10.1053/jhep.2001.25087 · Cited by 1,010
Endo, I., Gonen, M., Yopp, A. C., Dalal, K. M., Zhou, Q., Klimstra, D., D'Angelica, M., DeMatteo, R. P., Fong, Y., Schwartz, L., et al. (2008) · Annals of Surgery · doi:10.1097/sla.0b013e318176c4d3 · Cited by 865
de Jong, M. C., Nathan, H., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., Marques, H., Pulitano, C., Barroso, E., Clary, B. M., Aldrighetti, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.35.6519 · Cited by 729
Self-citationRising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?
Shaib, Y. H., Davila, J. A., McGlynn, K., & El-Serag, H. B. (2004) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.030 · Cited by 683
Spanish Experience in Liver Transplantation for Hilar and Peripheral Cholangiocarcinoma
Robles, R., Figueras, J., Turrión, V. S., Margarit, C., Moya, A., Varo, E., Calleja, J., Valdivieso, A., Valdecasas, J. C. G., López, P., et al. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000108702.45715.81 · Cited by 304
Choi, S.-B., Kim, K.-S., Choi, J.-Y., Park, S.-W., Choi, J.-S., Lee, W.-J., & Chung, J.-B. (2009) · Annals of Surgical Oncology · doi:10.1245/s10434-009-0631-1 · Cited by 304
Recurrence after operative management of intrahepatic cholangiocarcinoma
Hyder, O., Hatzaras, I., Sotiropoulos, G. C., Paul, A., Alexandrescu, S., Marques, H., Pulitano, C., Barroso, E., Clary, B. M., Aldrighetti, L., et al. (2013) · Surgery · doi:10.1016/j.surg.2012.12.005 · Cited by 281
Self-citationNathan, H., Pawlik, T. M., Wolfgang, C. L., Choti, M. A., Cameron, J. L., & Schulick, R. D. (2007) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-007-0282-0 · Cited by 245
Self-citationImpact of systemic inflammation on outcome following resection for intrahepatic cholangiocarcinoma
Gomez, D., Morris‐Stiff, G., Toogood, G. J., Lodge, J. P. A., & Prasad, R. K. (2008) · Journal of Surgical Oncology · doi:10.1002/jso.21001 · Cited by 158
Michiels, S., Piedbois, P., Burdett, S., Syz, N., Stewart, L., & Pignon, J.-P. (2005) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462305050154 · Cited by 154
Treatment outcomes and prognostic factors of intrahepatic cholangiocarcinoma
Dhanasekaran, R., Hemming, A. W., Zendejas, I. R., George, T. J., Nelson, D. R., Soldevila‐Pico, C., Firpi, R. J., Morelli, G., Clark, V., & Cabrera, R. (2013) · Oncology Reports · doi:10.3892/or.2013.2290 · Cited by 144
Fisher, S. B., Patel, S. H., Kooby, D. A., Weber, S. M., Bloomston, M., Cho, C. S., Hatzaras, I. S., Schmidt, C. R., Winslow, E. R., Staley, C. A., et al. (2012) · HPB · doi:10.1111/j.1477-2574.2012.00489.x · Cited by 84
Rosmarakis, E. S., Soteriades, E. S., Vergidis, P. I., Kasiakou, S. K., & Falagas, M. E. (2005) · The FASEB Journal · doi:10.1096/fj.04-3140lfe · Cited by 83
Prognostic Value of Cirrhosis for Intrahepatic Cholangiocarcinoma After Surgical Treatment
Li, Y., Li, H., Lv, P., Liu, G., Li, X., Tian, B., & Chen, D. (2011) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1419-8 · Cited by 66
Sulpice, L., Rayar, M., Boucher, É., Pelé, F., Pracht, M., Meunier, B., & Boudjéma, K. (2012) · Journal of Surgical Research · doi:10.1016/j.jss.2012.10.051 · Cited by 22
Cited by
Biliary tract cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Vogel, A., Bridgewater, J., Edeline, J., Kelley, R. K., Klümpen, H. J., Malka, D., Primrose, J. N., Rimassa, L., Stenzinger, A., Valle, J. W., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.506 · Cited by 718
Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma
Bertuccio, P., Malvezzi, M., Carioli, G., Hashim, D., Boffetta, P., El-Serag, H. B., La Vecchia, C., & Negri, E. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.03.013 · Cited by 648
Moris, D., Palta, M., Kim, C., Allen, P. J., Morse, M. A., & Lidsky, M. E. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21759 · Cited by 451
Liver resection and transplantation for intrahepatic cholangiocarcinoma
Mazzaferro, V., Gorgen, A., Roayaie, S., Droz dit Busset, M., & Sapisochin, G. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.11.020 · Cited by 355
EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma
Alvaro, D., Gores, G. J., Walicki, J., Hassan, C., Sapisochin, G., Komuta, M., Forner, A., Valle, J. W., Laghi, A., Ilyas, S. I., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.03.010 · Cited by 344
Metadata
- Authors
- Mavros, M. N., Economopoulos, K. P., Alexiou, V. G., & Pawlik, T. M.
- Venue
- JAMA Surgery
- Publisher
- American Medical Association (AMA)
- Published
- 2014-06-01
- Volume
- 149
- Issue
- 6
- Pages
- 565
- ISSN
- 2168-6254 (ISSN-L)
- OpenAlex
- W1963570372
- Cited by
- 808
- References
- 22
- FWCI
- 32.26
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.